Subscribe To
Psyched wellness announces key findings from 90-day oral toxicity study on amanita muscaria extract
Psyched Wellness (CSE:PSYC, OTCQB:PSYCF) Ltd said KGK, a contract research organisation, has reported key recent findings from the analysis of intest...
April 26, 2022, 8:52 am
Here is why nkarta is 40% up
Nkarta Inc. (NASDAQ: NKTX) is up 40% after announcing positive preliminary Phase 1 findings from its dose-finding trials of NKX101 and NKX019 in hemat...
April 25, 2022, 12:51 pm
Why nkarta stock is soaring today
Nkarta Inc (NASDAQ: NKTX) shares are trading higher Monday morning after the company announced positive preliminary Phase 1 data from independent dos...
April 25, 2022, 9:06 am
Context therapeutics reveals “encouraging” preclinical data from two cancer-treating pipeline programs
Context Therapeutics (NASDAQ:CNTX) Inc announced what it called “encouraging” preclinical data from two pipeline programs, including in vivo co...
April 11, 2022, 10:27 am
Gracell biotechnologies to present data at aacr annual meeting 2022 showcasing early first-in-human results for gc502 in r/r b-all
Allogeneic, off-the-shelf CAR-T therapy with CD19/CD7 dual-directed CAR shows promising early results in patients with r/r B-ALL PALO ALTO, Calif. and...
April 8, 2022, 4:00 pm
Why icosavax's shares are trading lower today
Icosavax Inc (NASDAQ: ICVX) has announced topline interim results from its ongoing Phase 1/2 trial of IVX-411, a VLP vaccine candidate displaying t...
March 25, 2022, 9:16 am
Anavex's blarcamesine and cassava sciences' simufilam: the stabilization period for alzheimer's disease
Aricept and blarcamesine limit further oxidative stress in Alzheimer's disease via agonism of Sigma-1 receptor...
March 22, 2022, 10:16 pm
Why are immunogen shares trading lower today
ImmunoGen Inc (NASDAQ: IMGN) shared full results from the SORAYA trial evaluating mirvetuximab in folate re...
March 21, 2022, 8:28 am
Celyad oncology to announce full year 2021 financial results and host conference call
MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD)...
March 17, 2022, 2:01 am
Theseus pharmaceuticals to present preclinical data characterizing next-generation epidermal growth factor receptor (egfr) inhibitors at the 2022 american association for cancer research (aacr) annual
CAMBRIDGE, Mass., March 8, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceut...
March 8, 2022, 5:01 pm
Theseus pharmaceuticals to present preclinical data characterizing next-generation epidermal growth factor receptor (egfr) inhibitors at the 2022 american association for cancer research (aacr) annual
CAMBRIDGE, Mass., March 8, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceut...
March 8, 2022, 5:01 pm
Theseus pharmaceuticals to present preclinical data characterizing next-generation epidermal growth factor receptor (egfr) inhibitors at the 2022 american association for cancer research (aacr) annual
CAMBRIDGE, Mass., March 8, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceut...
March 8, 2022, 5:01 pm
Relmada aces rel-1017 vs ketamine study for abuse potential
Relmada Therapeutics Inc (NASDAQ: RLMD) has announced topline results of the human abuse potential (HAP) study with REL-1017 for major depressive d...
February 23, 2022, 11:42 am
Relmada aces rel-1017 vs ketamine study for abuse potential
Relmada Therapeutics Inc (NASDAQ: RLMD) has announced topline results of the human abuse potential (HAP) study with REL-1017 for major depressive d...
February 23, 2022, 11:42 am
Relmada aces rel-1017 vs ketamine study for abuse potential
Relmada Therapeutics Inc (NASDAQ: RLMD) has announced topline results of the human abuse potential (HAP) study with REL-1017 for major depressive d...
February 23, 2022, 11:42 am
Biontech, medigene ink immunotherapy pact against cancer
BioNTech SE (NASDAQ: BNTX) and Medigene AG have entered a multi-target research collaboration to develop T cell ...
February 22, 2022, 7:31 am
Biontech, medigene ink immunotherapy pact against cancer
BioNTech SE (NASDAQ: BNTX) and Medigene AG have entered a multi-target research collaboration to develop T cell ...
February 22, 2022, 7:31 am
Biontech, medigene ink immunotherapy pact against cancer
BioNTech SE (NASDAQ: BNTX) and Medigene AG have entered a multi-target research collaboration to develop T cell ...
February 22, 2022, 7:31 am
Biovaxys says studies on bvx-0320, its haptenized sars-cov-2 s-spike protein vaccine, suggest superior cardiac safety
BioVaxys Technology Corp has revealed that studies on BVX-0320, its haptenized SARS-CoV-2 s-spike protein vaccine candidate, demonstrated that the va...
February 16, 2022, 9:48 am
Biovaxys says studies on bvx-0320, its haptenized sars-cov-2 s-spike protein vaccine, suggest superior cardiac safety
BioVaxys Technology Corp has revealed that studies on BVX-0320, its haptenized SARS-CoV-2 s-spike protein vaccine candidate, demonstrated that the va...
February 16, 2022, 9:48 am